Windtree Therapeutics is a biopharmaceutical company focused on the development of therapeutics. Co.'s primary product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure. Co.'s heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. In addition, Co.'s cardiovascular drug product candidates include rostafuroxin, a product candidate for the treatment of hypertension in patients with a specific genetic profile. We show 15 historical shares outstanding datapoints in our coverage of WINT's shares outstanding history.
Understanding the changing numbers of WINT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like WINT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching WINT by allowing them to research WINT shares outstanding history
as well as any other stock in our coverage universe. |
Free WINT Email Alerts:
Video: Shares Outstanding Importance
